Targeting immune overactivity in Down syndrome shows promise in… | HappeningNow.news

Health · 3 views

Targeting immune overactivity in Down syndrome shows promise in phase 2 clinical trial

In a first-of-its-kind clinical trial, researchers at the Linda Crnic Institute for Down Syndrome (Crnic Institute) at the University of Colorado Anschutz found that a medication targeting immune overactivity in people with Down syndrome…

Source AI Summary Published 10m ago Brief Under 1 min brief
Story intelligence
Coverage Single outlet Single-outlet story
Views 3 Community interest
Brief read Under 1 min brief 76 words

AI Summary

Researchers at the Linda Crnic Institute for Down Syndrome at the University of Colorado Anschutz conducted a phase 2 clinical trial of tofacitinib, a JAK inhibitor that blocks signals involved in immune responses and inflammation. The study found that the medication reduced underlying inflammation in people with Down syndrome. Participants also showed improvements in inflammatory skin conditions. The results were published in Cell Reports Medicine and suggest new research directions for brain health and Alzheimer’s disease.

AI summaries can be wrong sometimes—always verify important details using the source article.

How AI & Automation are used
Read original at Medical Xpress

More from Health

Continue reading recent Health coverage

Support HappeningNow

Independent AI-powered news analysis is reader-supported. Your contribution helps cover infrastructure, summaries, and continued platform development.

Support HappeningNow

Report an issue with this page